Lysogene signs €15m loan with EIB
France-based Lysogene, a phase three gene therapy platform company targeting central nervous system diseases, has signed a €15 million ($16.9...
France-based Lysogene, a phase three gene therapy platform company targeting central nervous system diseases, has signed a €15 million ($16.9...